Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group
{"title":"tezepelumab治疗重度变应性哮喘的临床疗效观察。","authors":"Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group","doi":"10.15586/aei.v53i5.1448","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.</p><p><strong>Results: </strong>We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV<sub>1</sub>. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 5","pages":"193-196"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice.\",\"authors\":\"Juan Carlos Miralles-López, Yulia Petryk Petryk, Juan José Cortés Collado, Francisco-Javier Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, Re-Asgramur Group\",\"doi\":\"10.15586/aei.v53i5.1448\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.</p><p><strong>Methods: </strong>This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.</p><p><strong>Results: </strong>We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV<sub>1</sub>. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.</p><p><strong>Conclusions: </strong>Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 5\",\"pages\":\"193-196\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i5.1448\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i5.1448","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice.
Introduction: Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.
Methods: This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.
Results: We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV1. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.
Conclusions: Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.
期刊介绍:
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.